Market by Product, Application, End-user, and Geography | Forecast 2021-2028
The detailed analysis of the global pharmaceutical continuous manufacturing market suggests that based on revenue, the market is likely to surge at a CAGR of 10.35% during the forecast years 2021-2028. Further, the market acquired $369.1 million in 2020, and is expected to attain revenue worth $937.7 million by 2028.
The continuous pharmaceutical manufacturing systems provide
significant advantages, such as reduced production fluctuation, improved
yields, low cost of operation and equipment, thereby fueling the studied
market’s growth.
Furthermore, continuous manufacturing is an innovative manufacturing
method, accomplished by employing end-to-end integration of manufacturing
subprocesses with a significant control strategies level. Moreover, it reduces
energy needs, is more time-efficient, and helps increase productivity, while
minimizing the overall waste. Hence, these factors are anticipated to offer the
global pharmaceutical continuous manufacturing market with lucrative
opportunities over the considered phase.
The study aims to get an overview of the pharmaceutical
continuous manufacturing market in terms of various factors. Within this
report, the key insight and the market description regarding the market have
been discussed. Also, Porter’s five forces model; the impact of COVID-19; legal,
policy, & regulatory framework; vendor scorecard; and market attractiveness
index, have been studied in detail.
The rise in initiatives by regulatory authorities for the
adoption of continuous manufacturing, growing acceptance of PCM systems, and
surging healthcare expenditures, are factors that are driving the global
market’s development. Additionally, the rising opportunities in the untapped
emerging economies and an increase in large molecules and biologics
manufacturing, are key opportunities that can be leveraged by the market to
reach the projected growth.
However, the major restraints, such as lack of demand for pharmaceutical continuous manufacturing systems in underdeveloped countries and growing customer expectations for better medicines, are obstructing the overall growth of the pharmaceutical continuous manufacturing market.
Key geographies covered in the pharmaceutical
continuous manufacturing market are:
• NorthAmerica: United States and Canada
• Europe:
Germany, United Kingdom, Spain, Italy, Russia, France, and Rest of Europe
• Asia-Pacific:
Japan, China, India, South Korea, ASEAN countries, New Zealand & Australia,
and Rest of Asia-Pacific
• LatinAmerica: Mexico, Brazil, and Rest of Latin America
• MiddleEast and Africa: Turkey, Saudi Arabia, South Africa, United Arab Emirates, and
Rest of Middle East & Africa
The segmentation analysis of the pharmaceutical
continuous manufacturing market includes:
• Market by Product:
o Integrated
Continuous System
o Semi-Continuous
System
o Control
& Software
• Market by Application:
o Final
Drug Product Manufacturing
o API
Manufacturing
• Market by End-user:
o Pharmaceutical
Companies
o Contract
Manufacturing Companies
o Other
End-users
The renowned companies profiled in the pharmaceutical continuous manufacturing market is Eli Lilly & Company, Munson Machinery Company, Siemens Healthineers, Syntegon, GEA Group AG, Coperion GmbH, Hosokawa Micron Corporation, Korsch AG, LB Bohle Maschinen + Verfahren GmbH, Gebruder Lodige Maschinenbau GmbH, Pfizer Inc, Thermofisher Scientific Inc, and Glatt GmbH.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. PORTER’S
FIVE FORCES MODEL
2.1.1. THREAT
OF NEW ENTRANTS
2.1.2. THREAT
OF SUBSTITUTE PRODUCTS
2.1.3. BARGAINING
POWER OF BUYERS
2.1.4. BARGAINING
POWER OF SUPPLIERS
2.1.5. COMPETITIVE
RIVALRY
2.2. IMPACT
OF COVID-19 ON PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
2.3. LEGAL,
POLICY, & REGULATORY FRAMEWORK
2.4. MARKET
ATTRACTIVENESS INDEX
2.5. VENDOR
SCORECARD
2.6. KEY
INSIGHTS
2.7. MARKET
DRIVERS
2.7.1. RISE
IN INITIATIVES BY REGULATORY AUTHORITIES FOR THE ADOPTION OF CONTINUOUS
MANUFACTURING
2.7.2. SURGING
ACCEPTANCE OF PHARMACEUTICAL CONTINUOUS MANUFACTURING SYSTEMS
2.7.3. RISING
HEALTHCARE EXPENDITURE
2.8. MARKET
RESTRAINTS
2.8.1. LACK
OF DEMAND FOR PCM SYSTEMS IN UNDERDEVELOPED ECONOMIES
2.8.2. RISING
CUSTOMER EXPECTATIONS FOR BETTER MEDICINES
2.9. MARKET
OPPORTUNITIES
2.9.1. INCREASING
OPPORTUNITIES IN THE UNTAPPED EMERGING ECONOMIES
2.9.2. SURGE
IN THE MANUFACTURING OF LARGE MOLECULES AND BIOLOGICS
3. GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY PRODUCT
3.1. INTEGRATED
CONTINUOUS SYSTEM
3.2. SEMI-CONTINUOUS
SYSTEM
3.3. CONTROL
& SOFTWARE
4. GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY APPLICATION
4.1. FINAL
DRUG PRODUCT MANUFACTURING
4.2. API
MANUFACTURING
5. GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET OUTLOOK - BY END-USER
5.1. PHARMACEUTICAL
COMPANIES
5.2. CONTRACT
MANUFACTURING ORGANIZATIONS
5.3. OTHER
END-USERS
6. GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET - REGIONAL OUTLOOK
6.1. NORTH
AMERICA
6.1.1. MARKET
BY PRODUCT
6.1.2. MARKET
BY APPLICATION
6.1.3. MARKET
BY END-USER
6.1.4. COUNTRY
ANALYSIS
6.1.4.1. UNITED
STATES
6.1.4.2. CANADA
6.2. EUROPE
6.2.1. MARKET
BY PRODUCT
6.2.2. MARKET
BY APPLICATION
6.2.3. MARKET
BY END-USER
6.2.4. COUNTRY
ANALYSIS
6.2.4.1. GERMANY
6.2.4.2. FRANCE
6.2.4.3. UNITED
KINGDOM
6.2.4.4. ITALY
6.2.4.5. RUSSIA
6.2.4.6. SPAIN
6.2.4.7. REST
OF EUROPE
6.3. ASIA-PACIFIC
6.3.1. MARKET
BY PRODUCT
6.3.2. MARKET
BY APPLICATION
6.3.3. MARKET
BY END-USER
6.3.4. COUNTRY
ANALYSIS
6.3.4.1. CHINA
6.3.4.2. INDIA
6.3.4.3. JAPAN
6.3.4.4. AUSTRALIA
& NEW ZEALAND
6.3.4.5. SOUTH
KOREA
6.3.4.6. ASEAN
COUNTRIES
6.3.4.7. REST
OF ASIA-PACIFIC
6.4. LATIN
AMERICA
6.4.1. MARKET
BY PRODUCT
6.4.2. MARKET
BY APPLICATION
6.4.3. MARKET
BY END-USER
6.4.4. COUNTRY
ANALYSIS
6.4.4.1. MEXICO
6.4.4.2. BRAZIL
6.4.4.3. REST
OF LATIN AMERICA
6.5. MIDDLE
EAST AND AFRICA
6.5.1. MARKET
BY PRODUCT
6.5.2. MARKET
BY APPLICATION
6.5.3. MARKET
BY END-USER
6.5.4. COUNTRY
ANALYSIS
6.5.4.1. SAUDI
ARABIA
6.5.4.2. UNITED
ARAB EMIRATES
6.5.4.3. TURKEY
6.5.4.4. SOUTH
AFRICA
6.5.4.5. REST
OF MIDDLE EAST & AFRICA
7. COMPANY
PROFILE
7.1. HOSOKAWA
MICRON CORPORATION
7.2. GEA
GROUP AG
7.3. LB
BOHLE MASCHINEN + VERFAHREN GMBH
7.4. THERMOFISHER
SCIENTIFIC INC
7.5. SIEMENS
HEALTHINEERS
7.6. ELI
LILLY & COMPANY
7.7. PFIZER
INC
7.8. GLATT
GMBH
7.9. SYNTEGON
(FORMERLY BOSCH PACKAGING TECHNOLOGY)
7.10. GEBRUDER
LODIGE MASCHINENBAU GMBH
7.11. KORSCH
AG
7.12. COPERION
GMBH
7.13. MUNSON
MACHINERY COMPANY
8. RESEARCH
METHODOLOGY & SCOPE
8.1. RESEARCH
SCOPE & DELIVERABLES
8.1.1. OBJECTIVES
OF STUDY
8.1.2. SCOPE
OF STUDY
8.2. SOURCES
OF DATA
8.2.1. PRIMARY
DATA SOURCES
8.2.2. SECONDARY
DATA SOURCES
8.3. RESEARCH
METHODOLOGY
8.3.1. EVALUATION
OF PROPOSED MARKET
8.3.2. IDENTIFICATION
OF DATA SOURCES
8.3.3. ASSESSMENT
OF MARKET DETERMINANTS
8.3.4. DATA
COLLECTION
8.3.5. DATA
VALIDATION & ANALYSIS
TABLE 1: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, 2021-2028 (IN $
MILLION)
TABLE 2: PROJECTED
NATIONAL HEALTHCARE EXPENDITURE 2021-2028 (IN $ BILLION)
TABLE 3: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2021-2028 (IN $
MILLION)
TABLE 4: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (IN $
MILLION)
TABLE 5: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, 2021-2028 (IN $
MILLION)
TABLE 6: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY REGION, 2021-2028 (IN $
MILLION)
TABLE 7: NORTH
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2021-2028
(IN $ MILLION)
TABLE 8: NORTH
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION,
2021-2028 (IN $ MILLION)
TABLE 9: NORTH
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, 2021-2028
(IN $ MILLION)
TABLE 10: NORTH
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028
(IN $ MILLION)
TABLE 11: EUROPE
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2021-2028 (IN $
MILLION)
TABLE 12: EUROPE
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (IN $
MILLION)
TABLE 13: EUROPE
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, 2021-2028 (IN $
MILLION)
TABLE 14: EUROPE
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (IN $
MILLION)
TABLE 15: ASIA-PACIFIC
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2021-2028 (IN $
MILLION)
TABLE 16: ASIA-PACIFIC
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION, 2021-2028 (IN $
MILLION)
TABLE 17: ASIA-PACIFIC
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, 2021-2028 (IN $
MILLION)
TABLE 18: ASIA-PACIFIC
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028 (IN $
MILLION)
TABLE 19: LATIN
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY, 2021-2028
(IN $ MILLION)
TABLE 20: LATIN
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT, 2021-2028
(IN $ MILLION)
TABLE 21: LATIN
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION,
2021-2028 (IN $ MILLION)
TABLE 22: LATIN
AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER, 2021-2028
(IN $ MILLION)
TABLE 23: MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY COUNTRY,
2021-2028 (IN $ MILLION)
TABLE 24: MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PRODUCT,
2021-2028 (IN $ MILLION)
TABLE 25: MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY APPLICATION,
2021-2028 (IN $ MILLION)
TABLE 26: MIDDLE
EAST AND AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY END-USER,
2021-2028 (IN $ MILLION)
FIGURE 1: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 2: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY INTEGRATED CONTINUOUS
SYSTEM, 2021-2028 (IN $ MILLION)
FIGURE 3: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY SEMI-CONTINUOUS SYSTEM,
2021-2028 (IN $ MILLION)
FIGURE 4: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTROL & SOFTWARE,
2021-2028 (IN $ MILLION)
FIGURE 5: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY FINAL DRUG PRODUCT
MANUFACTURING, 2021-2028 (IN $ MILLION)
FIGURE 6: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY API MANUFACTURING, 2021-2028
(IN $ MILLION)
FIGURE 7: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY PHARMACEUTICAL COMPANIES,
2021-2028 (IN $ MILLION)
FIGURE 8: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY CONTRACT MANUFACTURING
ORGANIZATIONS, 2021-2028 (IN $ MILLION)
FIGURE 9: GLOBAL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, BY OTHER END-USERS, 2021-2028
(IN $ MILLION)
FIGURE 10: UNITED
STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2020-2028 (IN $ MILLION)
FIGURE 11: CANADA
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2020-2028 (IN $ MILLION)
FIGURE 12: GERMANY
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 13: FRANCE
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 14: UNITED
KINGDOM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 15: ITALY
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 16: RUSSIA
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 17: SPAIN
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 18: REST OF
EUROPE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 19: CHINA
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 20: INDIA
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 21: JAPAN
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 22: AUSTRALIA
& NEW ZEALAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN
$ MILLION)
FIGURE 23: SOUTH
KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 24: ASEAN
COUNTRIES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 25: REST OF
ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $
MILLION)
FIGURE 26: MEXICO
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 27: BRAZIL
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 28: REST OF
LATIN AMERICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $
MILLION)
FIGURE 29: SAUDI
ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 30: UNITED
ARAB EMIRATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $
MILLION)
FIGURE 31: TURKEY
PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 32: SOUTH
AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET 2021-2028 (IN $ MILLION)
FIGURE 33: REST OF
MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET
2021-2028 (IN $ MILLION)